Abstract: A gasifier internal refractory coating has at least one region of a sintered material containing at least 45% by weight of chromium oxide (Cr2O3) and at least 1% by weight of zirconium oxide, at least 20% by weight of the zirconium oxide (ZrO2) being stabilized in the cubic and/or quadratic form.

Abstract: A translucent ceramic having a high light transmittance is provided. It contains a perovskite compound having a composition represented by a general formula: (Ba1-s-tSrsCat)(MxB1yB2z)vOw (where M contains at least one of Sn, Zr and Hf, B1 represents at least one of Mg, Zn, Y and In, B2 represents at least one of Ta and Nb, each of conditions of 0?s?0.99, 0.01?t?0.45, x+y+z=1, 0<x?0.9, 1.00?z/y?2.40, and 0.97?v?1.05 is satisfied, and w represents a positive number for maintaining electrical neutrality) as a primary component. This translucent ceramic can be used as, for example, an objective lens (2) of an optical pickup (9) to provide advantages. In another aspect some of M is replaced by Ti.

Abstract: A dielectric ceramic composition comprising a main component including Ba, Ca and Ti and having a perovskite crystal structure expressed by a general formula ABO3 and a fourth subcomponent including a compound of Zr; wherein a content of the fourth subcomponent with respect to 100 moles of the main component is larger than 0 mole and smaller than 5 moles in terms of Zr and, preferably, a segregation phase including the compound of Zr is provided.

Abstract: The present invention relates to highly dense translucent and transparent aluminium oxide components for applications, e.g. in the lighting industry, where a fine crystal size has to be obtained and stabilized for use at temperatures of 800° C. or more. Disclosed are high-strength polycrystalline alumina products which include 0.001-0.5 weight-% ZrO2 stabilizing a fine crystal size <2 ?m or, preferably, <1 ?m if used at temperatures of 800° C. or more. The microstructure exhibits an extremely high relative density enabling a high real in-line transmission >30% measured over an angular aperture of at most 0.5° at a sample thickness of 0.8 mm and with a monochromatic wavelength of light ?, preferably, of 645 nm.

Abstract: An exhaust gas purifying catalyst contains copper oxide, ZSM-5 and/or zeolite ?, and an oxide of magnesium and/or calcium is further added thereto. A process for purifying an exhaust gas using such a catalyst is also included. By using the catalyst, NOx in an exhaust gas containing much oxygen such as exhaust gas of diesel engines can be efficiently removed and oxidation of SO2 under high-temperature conditions can be suppressed.

Abstract: A gas diffusive electrode, an electrochemical device employing same, and methods of manufacturing and using same are provided. The gas diffusive electrode includes platinum powder and carbon powder or grain, to which carbon powder or grain whose particles are provided with a water-repellent film is further mixed. The gas diffusive electrode maintains an enhanced gas permeability.

Abstract: Highly dispersed supported catalyst nanoparticles are manufactured at temperatures below about 95° C. The catalyst nanoparticles are formed on a support using an organic anchoring agent. The anchoring agent molecules include at least two functional groups. One functional group is selected to bond with the catalyst atoms and the other functional group is selected to bond with the support material. The anchoring agent and its interaction with the support provide a template for the catalyst atoms. The catalyst nanoparticles are manufactured by treating the support material with a solution of the anchoring agent. A solution of the catalyst atoms is reacted with the anchoring agent molecules to form an intermediate supported catalyst. The supported intermediate catalyst is dried by heating at a temperature less than about 95° C. In an alternative embodiment, the catalyst atoms are reacted with the anchoring agent molecules prior to treating the support material with the anchoring agent.

Abstract: A hazardous substance treatment agent has a retainer and a transition metal oxide. The retainer has the specificity of retaining only a specific hazardous substance, such as a virus, a bacterium or a toxin, that has become mixed in or has the possibility of becoming mixed in a treatment subject, such as blood, that is in at least either a liquid or gaseous phase. By a photocatalytic action, the transition metal oxide inactivates said hazardous substance retained by the retainer.

Abstract: A method for producing a catalyst for a fuel cell is provided which is capable of improving output characteristics of the fuel cell. Metal fine particles making up the catalyst for the fuel cell to be used as a fuel electrode and air electrode are formed by reducing platinum salt with molybdenum carbonyl. The catalyst for the fuel cell is formed by supporting platinum-molybdenum fine particles on carbon particles. By employing this reducing method, platinum-molybdenum fine particles being small in size and high in dispersibility can be obtained, making the catalyst for the fuel cell highly active. By constructing the fuel and air electrodes using the catalyst for the fuel cell, high outputs from the fuel cell are made possible.

Abstract: A new method for preparing a supported catalyst is herein provided. A carbon nanotube structure such as a rigid porous structure is formed from single walled carbon nanotubes. A metal catalyst is then loaded or deposited onto the carbon nanotube structure. The loaded carbon nanotube is preferably ground to powder form.

Abstract: The instant invention is directed to the preparation of a slurry catalyst composition. The slurry catalyst composition is prepared in a series of steps, involving mixing a Group VIB metal oxide, particularly molybdenum and aqueous ammonia to form an aqueous mixture and sulfiding the mixture to form a slurry. The slurry is then promoted with a Group VIII metal. Subsequent steps involve mixing the slurry with a hydrocarbon oil, and combining the resulting mixture with hydrogen gas (under conditions which maintain the water in a liquid phase) to produce the active slurry catalyst.

Abstract: A sublimation ink carrier media is provided comprising a support sheet with a polymer film where a sublimation ink is printed in a pattern on the planar surface of the film. The polymer film is peelable from the planar surface of the support sheet, the polymer film is substantially non-extensible when the film is attached to the support sheet, the polymer film is extensible after being peeled from said carrier support sheet, and the polymer film has a melting temperature of at least 190° C. A process for the decoration of a shaped article by ink sublimation using the sublimation ink carrier media of the invention is also provided.

Abstract: The present invention is an aqueous composition for controlling or eradicating moss from undesirable locations such as lawns and golf course putting greens. The composition contains a fertilizer, a metal containing salt, a surfactant or wetting agent, and optionally, an acidic pH control agent. The composition can be provided in a form to be mixed and/or diluted by the end-user or in an aqueous form ready to be sprayed onto the infected area. Since the product can be broadly applied and encourages grass growth and development, it provides significant advantages over conventional moss control products intended for spot treating only.

Abstract: The reaction of the disulphided oil, as obtained from the caustic wash of liquefied petroleum gas, with 2,3,8,9,13,14-hexathia-5,6,11,12 -tetraazatricyclo [8.2.1.14,7]tetradeca-4,6,10,12-tetraene was carried out in one pot and one step to yield a corrosion inhibiting composition comprising predominantly of 2,5-bis(methyldithio)-1,3,4-thiadiazole, 2-methylthio-5-ethylthio-1,3,4-thiadiazole and 2,5-bis(ethyldithio)-1,3,4-thiadiazole, for application in fuels, lubes and greases.

Abstract: Mixtures of water immiscible components and water dispersible components, in combination with an optional coemulsifier and an optional coupling agent, provide synthetic (water based) emulsions that have enhanced lubricity, provide excellent cooling characteristics, are low foaming and biostable and can be made effectively transparent.

Abstract: An oil containing starch granule is provided comprising: (a) a starch to form an effective matrix for said granule; (b) a perfume oil comprising ingredients having a calculated Clog P of at least 3; and (c) an effective amount of an organic compound as herein described for inhibiting the migration of said oil to the surface of said starch granule.

Abstract: An oil containing starch granule is provided comprising: (a) a starch to form an effective matrix for said granule; (b) a perfume oil comprising ingredients having a calculated C log P of at least 3; and (c) an effective amount of an organic compound as herein described for inhibiting the migration of said oil to the surface of said starch granule.

Abstract: To provide a detergent composition which has little corrosion to a wiring material and is excellent in cleaning ability of a semiconductor substrate or semiconductor device on which the fine particles and the metal impurities are deposited. A detergent composition comprising a reducing agent, wherein the detergent composition has an oxidation-reduction potential at 25° C. of +0.2 V or less, and a pH at 25° C. of from 3 to 12; and a cleaning process of a semiconductor substrate or a semiconductor device using the detergent composition.

Abstract: The present invention is related to a method for producing a phospholipase by processing an expressed fungal peptide and to certain specified phospholipases. Furthermore the invention provides a method for producing cheese with a phospholipase.

Abstract: A cleaning composition with a limited number of natural ingredients contains alkyl polyglucoside, ethanol, glycerol, and an essential oil containing lemon oil or d-limonene. The cleaning composition optionally has a small amount of buffer, such as a natural inorganic buffer. The cleaning composition can be used to clean hard surfaces and cleans as well or better than commercial compositions containing synthetically derived cleaning agents.

Abstract: The invention relates to methods for potentiating, enhancing or restoring glucose responsivity in pancreatic islets or cells. The methods can be used as therapies for diseases caused by, or coincident with, aberrant glucose metabolism, such as Type II Diabetes Mellitus.

Abstract: An alternative HER-2/neu product, herstatin, consists of subdomains I and II from the ectodomain of p185HER-2 and a unique 79 amino acid C-terminus encoded by intron 8. Recombinant herstatin added to cells was found to bind to and inhibit p185HER-2. The effects of ectopic expression of herstatin in combination with either p185HER-2 or with its homolog, the EGF receptor, in several cell lines was studied. Cotransfection of herstatin with HER-2 inhibited p185HER-2 levels and caused an approximate 8 fold reduction in p185 tyrosine phosphorylation. Inhibition of p185HER-2 tyrosine phosphorylation corresponded to a dramatic decline in colony formation by cells that coexpressed p185HER-2 and herstatin. Herstatin also interfered with EGF activation of the EGF receptor in cotransfected cells demonstrated by impaired receptor tyrosine phosphorylation, reduced receptor down-regulation, and growth suppression.

Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.

Abstract: A method for modulating Nod1 activity wherein said method comprises the steps of providing cells expressing a functional Nod1; and bringing said cells into contact with a molecule related to compositions comprising a molecule related to MTP and use of a molecule related to MTP for modulating inflammation and/or apoptosis.

Abstract: The subject invention pertains to the use of peptide fragments of cadherins (including cadherin-like proteins). The subject invention includes a cell (and use thereof) comprising a polynucleotide that expresses the peptide fragment. The subject invention includes methods of feeding the peptides to insects. In preferred embodiments, the peptides are fed to target insects together with one or more insecticidal proteins, preferably (but not limited to) B.t. Cry proteins. When used in this manner, the peptide fragment can not only enhance the apparent toxin activity of the Cry protein against the insect species that was the source of the receptor but also against other insect species. Preferably, the cadherin is a Bacillus thuringiensis (B.t.) insecticidal crystal protein (Cry) toxin receptor. Preferably, the peptide fragment is a binding domain of the receptor. In some preferred embodiments, the peptide is the binding domain nearest to the membrane proximal ectodomain.

Abstract: Metallopeptide compositions are provided for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction. The metallopeptides include at least one, and preferably two, aromatic amino acid side chain moieties, and are further characterized in that the metallopeptides preferably do not bind or significantly bind to a melanocortin receptor.

Abstract: A cosmetic and/or dermatological and/or pharmaceutical composition includes, as the active ingredient, at least one peptide with sequence X1-Y-Phe-Thr-X2-Ala-Thr-Z-Ile-X3-Leu-X4-Phe-Leu-X5; wherein: X1, X2, X3, X4, X5=Arg, Lys, His; Y=Asp, Glu; Z=Asn, Gln. The invention also relates to the use of said composition in order to treat, inter alia, the signs of cutaneous ageing. Moreover, the invention relates to the cosmetic skin treatment method using the peptide.

Abstract: It is intended to provide novel polypeptides which specifically inhibit the activity of a mechano-sensitive channel; and mechano-sensitive channel inhibitors or remedies for atrial fibrillation containing these polypeptides or salts thereof. The above objects can be achieved by using polypeptides having amino acid sequences represented by SEQ ID NO:1 (TVP003), SEQ ID NO:2 (TVP004) and SEQ ID NO:3 (TVP005), salts of these polypeptides, and mechano-sensitive channel inhibitors or remedies for atrial fibrillation containing the same.

Abstract: The peptide Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine (SEQ ID NO.1) is disclosed with its use as a pharmaceutical composition in reducing symptoms of viral disease and stimulating properties of immune system in a subject. A method is also disclosed for making a pharmaceutical composition comprising providing an Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine (SEQ ID NO.1) peptide and mixing said peptide with a pharmaceutical acceptable carrier.

Abstract: The hexuronic acid derivative represented by the following formula 1 or a salt thereof is used as an active ingredient of a heparin/heparan sulfate sulfotransferase inhibitor. In the formula, each of R1, R2, and R3 independently represent(s) SO3? or H which may have a substituent, provided that at least one thereof represents SO3?; X represents OR4, SR4, N(R4)2, or C(R4)3, R4 independently represents H, alkyl, alkenyl, alkynyl, acyl, aryl, or aralkyl group; one of R5 and R6 represents COOH while the other represents H; and the wavy line represents ?-glycosidic bond or ?-glycosidic bond.

Abstract: The present invention provides a method for preparing a pharmaceutical formulation containing ivermectin and a method and composition that can contain ivermectin plus hexahydropyrazinoisoquinolines and tetrahydropyrimidines. Examples of these include praziquantel and pyrantel. A pharmaceutical formulation is provided for use in the treatment of helminthiasis of mammals, and particularly tapeworm, hookworm, roundworm and heartworm of domestic animals and farm animals. The present invention also provides a method of treating helminthiasis in mammals, which method comprises administering to the mammal in need thereof an anthelmintically effective amount of a pharmaceutical formulation of the invention.

Abstract: The present invention provides a method for preparing a pharmaceutical formulation containing ivermectin and a method and composition that can contain ivermectin plus hexahydropyrazinoisoquinolines, tetrahydropyrimidines and benzimidazoles or febantel. Examples of hexahydropyrazinoisoquinolines, tetrahydropyrimidines and benzimidazoles include praziquantel, pyrantel pamoate and fenbendazole, respectively. A pharmaceutical formulation is provided for use in the treatment of helminthiasis of mammals, and particularly tapeworm, hookworm, roundworm, whipworm and heartworm of domestic animals and farm animals. The present invention also provides a method of treating helminthiasis in mammals, which method comprises administering to the mammal in need thereof an anthelmintically effective amount of a pharmaceutical formulation of the invention.

Abstract: Disclosed is a process for transfecting genetic material into a mammalian cell to alter endogenous properties of the cell. The process comprises designing a polynucleotide for transfection. Then the polynucleotide is inserted into a mammalian blood vessel. Prior to insertion, subsequent to insertion, or concurrent with insertion the permability of the vessel is increased using an exterior cuff and immunosuppression is applied thereby the genetic material is delivered to the parenchymal cell.

Abstract: The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.

Abstract: The invention provides antisense DNA oligonucleotides which are effective in inhibiting the expression of a wild type COL1A1 gene, wherein said oligonucleotides are used in inhalation therapy to treat various lung diseases.

Abstract: The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.

Abstract: The present invention provides a therapeutic method for treating diabetic kidney disease, e.g., diabetic nephropathy that includes the administration of an effective amount of an A2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor.

Abstract: The present invention relates to novel uridine esters of the general formula wherein R represents a carboxylic acid residue, preferably a fatty acid residue and R? represents hydrogen or a hydroxy group, their use as pharmaceutically active agents against a variety of diseases, methods for the preparation of said uridine esters and pharmaceutical compositions containing at least one uridine ester as active ingredient. The present invention relates also to a drug combination comprising free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate and/or deoxyuridine monophosphate, and to the use of such a drug combination.

Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Abstract: The invention provides prodrugs of inhibitors of PI-3 kinase. The compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

Abstract: The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia.

Abstract: This disclosure provides compounds of Formula I as described herein having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with indole and azaindole piperazine diamide derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.

Abstract: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, d

Abstract: The present invention is directed to compounds comprising a 2,3-diphenylquinoxaline moiety which inhibit the activity of Akt, a serine/threonine protein kinase.

Abstract: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, which act as ligands for the ?7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

Abstract: Compounds of general formula: wherein R1 and R2 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Abstract: The present invention provides a process for the preparation of 6-[(substituted)phenyl]-triazolopyrimidine dicarboxylic acid salt and as a hydrated salt having the structural formula (I) wherein: R1 is CF3 or C2F5; R2 is H or C1-C3 alkyl; n is an integer of 2, 3, or 4; X is Cl or Br; R3 and R4 are each independently H or C1-C3 alkyl; or R3 and R4 when optionally taken together with the nitrogen atom to which each is attached form a 4 to 6 membered saturated heterocyclic ring having 1-2 nitrogen atoms and 0-1 oxygen atoms or 0-1 sulfur atoms, and optionally substituted with R5; R5 is C1-C3 alkyl; wherein the dotted line is an optional bond.

Abstract: A compound having excellent adenosine receptor (A1, A2A, A2B receptor) antagonistic action, of the following formula, a salt thereof or a solvate of them: wherein, R1 and R2, same or different, each represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, an aromatic hydrocarbon cyclic group, an acyl group or an alkylsulfonyl group, which groups may be substituted (except the hydrogen atom); R3 represents a hydrogen atom, a halogen atom, a cyano group, an alkyl group, an alkenyl group, an alkynyl group, an aromatic hydrocarbon cyclic group, a nitrogen atom, an oxygen atom or a sulfur atom, which groups may be substituted (except the hydrogen atom, the halogen atom and the cyano group); R4 represents an aromatic hydrocarbon cyclic group which may be substituted, and R5 represents an aromatic hydrocarbon cyclic group which may be substituted.

Abstract: New lamellarins are provided of the general formula III or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof

Abstract: A method of treating cancer including administering to a subject in need thereof an effective amount of a compound of the formula 1: wherein R1, R2, R3, R4, and n are as defined herein.